Applied DNA Sciences Files 8-K on Financials
Ticker: BNBX · Form: 8-K · Filed: May 10, 2024 · CIK: 744452
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
APDN filed an 8-K detailing financial results and exhibits.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition, as well as presenting financial statements and exhibits. The filing details the company's financial performance and provides relevant exhibits for investors to review.
Why It Matters
This filing provides investors with crucial updates on Applied DNA Sciences' financial health and operational results, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not inherently introduce new risks.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- May 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 50 Health Sciences Drive (address) — Business and mailing address
- Stony Brook (city) — City of business and mailing address
- New York (state) — State of business and mailing address
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 10, 2024.
What is the state of incorporation for Applied DNA Sciences, Inc.?
Applied DNA Sciences, Inc. is incorporated in Delaware.
What is the business and mailing address of Applied DNA Sciences, Inc.?
The business and mailing address is 50 Health Sciences Drive, Stony Brook, New York.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-10 16:07:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2414131d1_8k.htm (8-K) — 25KB
- tm2414131d1_ex99-1.htm (EX-99.1) — 104KB
- image_004.jpg (GRAPHIC) — 7KB
- 0001104659-24-059893.txt ( ) — 318KB
- apdn-20240510.xsd (EX-101.SCH) — 3KB
- apdn-20240510_lab.xml (EX-101.LAB) — 33KB
- apdn-20240510_pre.xml (EX-101.PRE) — 22KB
- tm2414131d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 10, 2024, Applied DNA Sciences, Inc. ("Applied DNA Sciences" or the "Company") issued a press release announcing its results of operations for the three-month period ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits 99.1 Press Release of Applied DNA Sciences, Inc. dated May 10, 2024 regarding results of operations for the three-month period March 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 10, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release issued by Applied DNA Sciences, Inc. dated May 10, 2024 regarding results of operations for the three-month period ended March 31, 2024.